Patents by Inventor Feda Azab

Feda Azab has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydrogels for localized radiotherapy
    Patent number: 10548996
    Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
    Type: Grant
    Filed: March 30, 2015
    Date of Patent: February 4, 2020
    Assignee: WASHINGTON UNIVERSITY
    Inventors: Abdel Kareem Azab, Pilar de la Puente, Feda Azab
  • HYDROGELS FOR LOCALIZED RADIOTHERAPY
    Publication number: 20170209606
    Abstract: Radioactive hydrogels for the delivery of localized radiotherapy, methods of making the radioactive hydrogels, and methods of using the radioactive hydrogels are disclosed. A radioisotope may be conjugated to a high molecular weight molecule, which may be encapsulated in a microparticle, where the microparticle is then dispersed within a hydrogel. The radioactive hydrogel may prevent leakage of the radioisotope to provide radiotherapy to a surgical margin while minimizing damage to surrounding normal tissue.
    Type: Application
    Filed: March 30, 2015
    Publication date: July 27, 2017
    Inventors: Abdel Kareem Azab, Pilar de la Puente, Feda Azab
  • BIOMARKERS FOR MULTIPLE MYELOMA
    Publication number: 20160299148
    Abstract: The present disclosure is directed to a molecular signature useful in the identification multiple myeloma cells. The molecular signature advantageously identifies multiple myeloma cells under both normoxic and hypoxic conditions. The disclosed molecular signature may be used to diagnose, prognose and monitor multiple myeloma.
    Type: Application
    Filed: November 24, 2014
    Publication date: October 13, 2016
    Inventors: Feda Azab, Barbara Muz, Abdel Kareem Azab